Valvular & structural heart disease

Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial

CirculationPublished Randomised controlled trial

Authors' conclusion

In patients with severe aortic stenosis and SAA (women in the majority), there was no evidence of superiority of contemporary TAVR versus SAVR in valve hemodynamic results. After a median follow-up of 2 years, there were no differences in clinical outcomes between groups.

Study context

Population
Severe AS and small aortic annulus (mean diameter <23 mm)140 (93%) women
Participants
151 participants
Comparison
Transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR)
  • TAVRn = 77
  • SAVRn = 74reference
Primary endpoint
Impaired valve hemodynamics (severe prosthesis patient mismatch or moderate-severe aortic regurgitation) by Doppler echocardiography, central core laboratory
Follow-up
60 days
Methodological detailsmulticentre, international, 15 university hospitals
  • Multicentre
  • International
  • 15 university hospitals

Primary result

As reported in the abstract

GroupValueModerate-severe aortic regurgitation
TAVR5.6%0
SAVR10.3%0

Value

TAVR5.6%
SAVR10.3%

Moderate-severe aortic regurgitation

TAVR0
SAVR0
  • TAVR vs SAVR: P = 0.30 — severe prosthesis patient mismatch

Secondary outcomes

Mortality · 30 days

P = 1.00

Mortality · median follow-up 2 (IQR 1-4) years

P = 0.89

Stroke · median follow-up 2 (IQR 1-4) years

P = 0.95

Cardiac hospitalization · median follow-up 2 (IQR 1-4) years

P = 0.80

OutcomeTAVRSAVRP value
Stroke · 30 days0 events2.7%P = 0.24

Original publication

Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial. Circulation. Published 26 October 2023. doi:10.1161/circulationaha.123.067326

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.